Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
109M
-
Number of holders
-
40
-
Total 13F shares, excl. options
-
5.14M
-
Shares change
-
-1.21M
-
Total reported value, excl. options
-
$6.93M
-
Value change
-
-$1.68M
-
Number of buys
-
18
-
Number of sells
-
-12
-
Price
-
$1.35
Significant Holders of ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) as of Q4 2023
45 filings reported holding ONCY - ONCOLYTICS BIOTECH INC - Common Stock, no par value as of Q4 2023.
ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) has 40 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.14M shares
of 109M outstanding shares and own 4.7% of the company stock.
Largest 10 shareholders include Anson Funds Management LP (3.81M shares), MORGAN STANLEY (231K shares), INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC (200K shares), MILLENNIUM MANAGEMENT LLC (128K shares), CITADEL ADVISORS LLC (114K shares), Advisor Resource Council (100K shares), CIBC WORLD MARKET INC. (60.9K shares), COMMONWEALTH EQUITY SERVICES, LLC (55.6K shares), ROYAL BANK OF CANADA (54.9K shares), and GEODE CAPITAL MANAGEMENT, LLC (41.9K shares).
This table shows the top 40 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.